RU2018142943A - Композиции для лечения нарушений кислотно-основного равновесия - Google Patents
Композиции для лечения нарушений кислотно-основного равновесия Download PDFInfo
- Publication number
- RU2018142943A RU2018142943A RU2018142943A RU2018142943A RU2018142943A RU 2018142943 A RU2018142943 A RU 2018142943A RU 2018142943 A RU2018142943 A RU 2018142943A RU 2018142943 A RU2018142943 A RU 2018142943A RU 2018142943 A RU2018142943 A RU 2018142943A
- Authority
- RU
- Russia
- Prior art keywords
- meq
- less
- composition
- ability
- paragraphs
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 229920000642 polymer Polymers 0.000 claims 6
- 150000001412 amines Chemical class 0.000 claims 5
- 239000000872 buffer Substances 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 208000010444 Acidosis Diseases 0.000 claims 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 3
- 206010027417 Metabolic acidosis Diseases 0.000 claims 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 210000000813 small intestine Anatomy 0.000 claims 3
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 210000004051 gastric juice Anatomy 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 229910052700 potassium Inorganic materials 0.000 claims 2
- 239000011591 potassium Substances 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims 1
- 125000006325 2-propenyl amino group Chemical group [H]C([H])=C([H])C([H])([H])N([H])* 0.000 claims 1
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 claims 1
- 239000012062 aqueous buffer Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000008367 deionised water Substances 0.000 claims 1
- 229910021641 deionized water Inorganic materials 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940085991 phosphate ion Drugs 0.000 claims 1
- 239000001294 propane Substances 0.000 claims 1
- 238000010526 radical polymerization reaction Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000008961 swelling Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F8/00—Chemical modification by after-treatment
- C08F8/02—Alkylation
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
- C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
- C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
- C08F226/04—Diallylamine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662333059P | 2016-05-06 | 2016-05-06 | |
| US62/333,059 | 2016-05-06 | ||
| US201662350686P | 2016-06-15 | 2016-06-15 | |
| US62/350,686 | 2016-06-15 | ||
| US201662408885P | 2016-10-17 | 2016-10-17 | |
| US62/408,885 | 2016-10-17 | ||
| US201662414966P | 2016-10-31 | 2016-10-31 | |
| US62/414,966 | 2016-10-31 | ||
| PCT/US2017/031378 WO2017193050A1 (en) | 2016-05-06 | 2017-05-05 | Compositions for treating acid-base disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018142943A true RU2018142943A (ru) | 2020-06-08 |
| RU2018142943A3 RU2018142943A3 (https=) | 2020-08-10 |
Family
ID=59315687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018142943A RU2018142943A (ru) | 2016-05-06 | 2017-05-05 | Композиции для лечения нарушений кислотно-основного равновесия |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US11406661B2 (https=) |
| EP (3) | EP3452057A1 (https=) |
| JP (3) | JP7071284B2 (https=) |
| KR (1) | KR102655774B1 (https=) |
| CN (2) | CN109414453B (https=) |
| AU (3) | AU2017261337A1 (https=) |
| BR (1) | BR112018072714A2 (https=) |
| CA (1) | CA3023264A1 (https=) |
| IL (2) | IL308673A (https=) |
| MA (3) | MA44875A (https=) |
| MX (1) | MX2018013476A (https=) |
| MY (1) | MY197091A (https=) |
| RU (1) | RU2018142943A (https=) |
| SG (1) | SG11201809605PA (https=) |
| WO (3) | WO2017193050A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3003327B1 (en) | 2013-06-05 | 2017-08-09 | Tricida Inc. | Proton-binding polymers for oral administration |
| RS61409B1 (sr) | 2014-12-10 | 2021-03-31 | Tricida Inc | Polimeri koji vezuju protone za oralnu primenu opis |
| CN109414453B (zh) | 2016-05-06 | 2023-02-17 | 特里赛达公司 | 用于治疗酸碱失衡的组合物 |
| US10934380B1 (en) | 2017-09-25 | 2021-03-02 | Tricida, Inc. | Crosslinked poly(allylamine) polymer pharmaceutical compositions |
| JP7018451B2 (ja) * | 2017-10-16 | 2022-02-10 | 富士フイルム株式会社 | 高リン血症治療剤および粒子 |
| AU2018360868B2 (en) * | 2017-11-03 | 2025-01-02 | Tricida, Inc. | Method of treating acid-base disorders |
| CA3080651A1 (en) | 2017-11-03 | 2019-05-09 | Tricida, Inc. | Compositions for and method of treating acid-base disorders |
| WO2019236639A1 (en) * | 2018-06-04 | 2019-12-12 | Tricida, Inc. | Method of treating acid-base disorders |
| CA3102765A1 (en) * | 2018-06-04 | 2019-12-12 | Tricida, Inc. | Method of treating acid-base disorders |
| SI4053179T1 (sl) | 2021-03-01 | 2026-01-30 | Renosis, Inc. | Farmacevtski sestavki iz premreženega poli(alilaminskega) polimera |
| IL305604A (en) | 2021-03-01 | 2023-11-01 | Tricida Inc | Pharmaceutical preparations of cross-linked poly(allylamine) polymer |
| CN118510524A (zh) * | 2021-12-14 | 2024-08-16 | 上海石趣医药科技有限公司 | 氧化银和/或其水合物在制备药物中的用途 |
| WO2023109826A1 (zh) * | 2021-12-14 | 2023-06-22 | 上海石趣医药科技有限公司 | 碳酸银在制备药物中的用途 |
Family Cites Families (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6444221B1 (en) | 1992-06-30 | 2002-09-03 | Howard K. Shapiro | Methods of treating chronic inflammatory diseases using carbonyl trapping agents |
| US20050090553A1 (en) | 1992-06-30 | 2005-04-28 | Shapiro Howard K. | Compositions and method for treatment of chronic inflammatory diseases |
| CA2202397C (en) | 1994-10-17 | 2002-07-16 | Peter W. Stacpoole | Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and methods for treatment of metabolic and cardiovascular disorders |
| US5496545A (en) | 1993-08-11 | 1996-03-05 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
| US5667775A (en) | 1993-08-11 | 1997-09-16 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
| US5648355A (en) | 1994-02-09 | 1997-07-15 | Kos Pharmaceutical, Inc. | Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin |
| TW474813B (en) | 1994-06-10 | 2002-02-01 | Geltex Pharma Inc | Alkylated composition for removing bile salts from a patient |
| US20020006899A1 (en) | 1998-10-06 | 2002-01-17 | Pospisilik Andrew J. | Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals |
| US5753706A (en) | 1996-12-16 | 1998-05-19 | Hsu; Chen Hsing | Methods for treating renal failure |
| AUPO758297A0 (en) | 1997-06-27 | 1997-07-24 | Rowe, James Baber | Control of acidic gut syndrome |
| US6726905B1 (en) | 1997-11-05 | 2004-04-27 | Genzyme Corporation | Poly (diallylamines)-based phosphate binders |
| WO1999040990A1 (en) | 1998-02-17 | 1999-08-19 | University Of Maryland | Anion binding polymers and the use thereof |
| US6485703B1 (en) | 1998-07-31 | 2002-11-26 | The Texas A&M University System | Compositions and methods for analyte detection |
| US6271264B1 (en) | 1998-12-01 | 2001-08-07 | Geltex Pharmaceuticals, Inc. | Polymers containing spirobicyclic ammonium moieties as bile acid sequestrants |
| US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
| GB9927088D0 (en) | 1999-11-17 | 2000-01-12 | Secr Defence | Use of poly(diallylamine) polymers |
| AU2001241076A1 (en) | 2000-03-09 | 2001-09-17 | Hisamitsu Pharmaceutical Co. Inc. | Crosslinked anion-exchange resin or salt thereof |
| WO2001066607A1 (en) | 2000-03-09 | 2001-09-13 | Hisamitsu Pharmaceutical Co., Inc. | Crosslinked anion-exchange resin or salt thereof and phosphorus adsorbent comprising the same |
| US20030091530A1 (en) | 2000-03-13 | 2003-05-15 | Takeshi Goto | Preventives and/or remedies for hyperphosphatemia |
| JP2002028737A (ja) | 2000-07-07 | 2002-01-29 | Fujitsu Ltd | プレス打ち抜き加工方法及びプレス打ち抜き加工装置 |
| AT409630B (de) * | 2000-12-13 | 2002-09-25 | Dsm Fine Chem Austria Gmbh | Alkylierung von n-bzw. amino- oder ammoniumgruppen haltigen, vernetzten polymeren |
| WO2002085381A1 (en) | 2001-04-18 | 2002-10-31 | Genzyme Corporation | Method for treating gout and binding uric acid |
| DE60212819T2 (de) | 2001-04-18 | 2006-11-23 | Genzyme Corp., Cambridge | Salzformarme polyallylamine |
| CA2478599A1 (en) | 2002-03-11 | 2003-09-18 | Novartis Ag | Salts of nateglinide |
| WO2004069866A1 (en) | 2003-02-10 | 2004-08-19 | Autogen Research Pty Ltd | Therapeutic molecules |
| TWI335218B (en) | 2003-02-19 | 2011-01-01 | Panion & Bf Biotech Inc | Ferric organic compounds, uses thereof and methods of making same |
| US7608674B2 (en) | 2003-11-03 | 2009-10-27 | Ilypsa, Inc. | Pharmaceutical compositions comprising cross-linked small molecule amine polymers |
| US7459502B2 (en) | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
| US7767768B2 (en) | 2003-11-03 | 2010-08-03 | Ilypsa, Inc. | Crosslinked amine polymers |
| US7385012B2 (en) | 2003-11-03 | 2008-06-10 | Ilypsa, Inc. | Polyamine polymers |
| US7335795B2 (en) | 2004-03-22 | 2008-02-26 | Ilypsa, Inc. | Crosslinked amine polymers |
| US7449605B2 (en) | 2003-11-03 | 2008-11-11 | Ilypsa, Inc. | Crosslinked amine polymers |
| CA2551528A1 (en) | 2003-12-31 | 2005-07-21 | Genzyme Corporation | Enteric coated aliphatic amine polymer bile acid sequestrants |
| KR20060128972A (ko) | 2004-01-29 | 2006-12-14 | 각고호우징 게이오기주크 | 적혈구 기능 수식 물질 |
| BRPI0509365B8 (pt) | 2004-03-30 | 2021-05-25 | Ilypsa Inc | composição farmacêutica, kit farmacêutico, e, uso da referida composição |
| US7429394B2 (en) | 2004-03-30 | 2008-09-30 | Relypsa, Inc. | Ion binding compositions |
| US7556799B2 (en) | 2004-03-30 | 2009-07-07 | Relypsa, Inc. | Ion binding polymers and uses thereof |
| US8192758B2 (en) | 2004-03-30 | 2012-06-05 | Relypsa, Inc. | Ion binding compositions |
| US8282960B2 (en) | 2004-03-30 | 2012-10-09 | Relypsa, Inc. | Ion binding compositions |
| US7854924B2 (en) | 2004-03-30 | 2010-12-21 | Relypsa, Inc. | Methods and compositions for treatment of ion imbalances |
| US8399025B2 (en) | 2004-06-04 | 2013-03-19 | Board Of Regents, The University Of Texas System | Polyamine modified particles |
| US8501676B2 (en) | 2004-07-19 | 2013-08-06 | N.V. Nutricia | Preparation for use of aspartate for regulating glucose levels in blood |
| DE102004035808A1 (de) | 2004-07-21 | 2006-03-16 | Kasch, Helmut, Dr. | Ammoniumsalze und Ammoniumsalz-Mineralsalzchlatrate als Transport- und Wirkform für pharmazeutische-medizinische und als Phasentransfermittel für chemische Anwendungen |
| US8569277B2 (en) | 2004-08-11 | 2013-10-29 | Palo Alto Investors | Methods of treating a subject for a condition |
| US20080214440A1 (en) | 2004-10-08 | 2008-09-04 | Forbes Medi-Tech (Research), Inc. | Vasoactive intestinal polypeptide compositions |
| US20070293429A1 (en) | 2004-10-08 | 2007-12-20 | Therapei Pharmaceuticals, Inc. | Vasoactive Intestinal Polypeptide Compositions |
| US7985418B2 (en) | 2004-11-01 | 2011-07-26 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
| ITME20040015A1 (it) | 2004-12-07 | 2005-03-07 | Vincenzo Savica | Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico. |
| US20080200533A1 (en) | 2005-07-04 | 2008-08-21 | Ramu Krishnan | Drug or Pharmaceutical Compounds and a Preparation Thereof |
| CA2619591C (en) | 2005-08-18 | 2020-03-24 | Globoasia, Llc | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
| US8986669B2 (en) | 2005-09-02 | 2015-03-24 | Genzyme Corporation | Method for removing phosphate and polymer used therefore |
| WO2007038801A2 (en) | 2005-09-30 | 2007-04-05 | Ilypsa, Inc. | Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof |
| BRPI0616603A2 (pt) | 2005-09-30 | 2012-12-25 | Ilypsa Inc | mÉtodo para preparar um compàsito de nécleo-envoltàrio, e para a manufatura de um medicamento, composiÇço farmacÊutica, e, uso da mesma |
| WO2007041569A1 (en) | 2005-09-30 | 2007-04-12 | Ilypsa, Inc. | Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal |
| EP1945196A2 (en) | 2005-11-08 | 2008-07-23 | Genzyme Corporation | Magnesium-containing polymers for hyperphosphatemia |
| WO2007055044A1 (ja) | 2005-11-08 | 2007-05-18 | Ajinomoto Co., Inc. | 麻酔覚醒促進剤 |
| ITMI20052461A1 (it) | 2005-12-22 | 2007-06-23 | Univ Degli Studi Milano | Sistemi microparticellari per la somministrazione orale di sostanze biologicamente attive |
| RU2008136081A (ru) | 2006-02-14 | 2010-03-20 | Тева Фармасьютикл Индастриес Лтд. (Il) | Фармацевтические составы с алифатическими аминными полимерами и способы их производства |
| EP2016114A2 (en) | 2006-05-05 | 2009-01-21 | Genzyme Corporation | Amine condensation polymers as phosphate sequestrants |
| EP2043627A2 (en) | 2006-07-05 | 2009-04-08 | Genzyme Corporation | Iron(ii)-containing treatments for hyperphosphatemia |
| US20100124542A1 (en) | 2006-07-18 | 2010-05-20 | Genzyme Corporation | Amine dendrimers |
| WO2008016729A1 (en) | 2006-08-04 | 2008-02-07 | Nastech Pharmaceutical Company Inc. | Compositions for intranasal delivery of human insulin and uses thereof |
| CA2749074A1 (en) | 2006-09-01 | 2008-05-29 | Usv Limited | Process for the preparation of sevelamer hydrochloride and formulation thereof |
| EP2068819A4 (en) | 2006-09-01 | 2011-04-20 | Genzyme Corp | Dendrimer COMPOSITIONS |
| US7964182B2 (en) | 2006-09-01 | 2011-06-21 | USV, Ltd | Pharmaceutical compositions comprising phosphate-binding polymer |
| US7868045B2 (en) | 2006-09-06 | 2011-01-11 | Sucampo Ag | Method for promoting gastrointestinal bicarbonate secretion |
| EP2066293A2 (en) | 2006-09-29 | 2009-06-10 | Genzyme Corporation | Amide dendrimer compositions |
| US8163799B2 (en) | 2006-12-14 | 2012-04-24 | Genzyme Corporation | Amido-amine polymer compositions |
| JP2010519298A (ja) | 2007-02-23 | 2010-06-03 | ゲンズイメ コーポレーション | アミンポリマー組成物 |
| US20080207766A1 (en) | 2007-02-27 | 2008-08-28 | Agi Therapeutics Research Ltd. | Methods and compositions for treating at least one upper gastrointestinal symptom |
| JP2010520285A (ja) | 2007-03-08 | 2010-06-10 | ゲンズイメ コーポレーション | スルホンポリマー組成物 |
| TWI445540B (zh) | 2007-04-20 | 2014-07-21 | Ajinomoto Kk | 抗低體溫組成物 |
| US20100166696A1 (en) | 2007-04-27 | 2010-07-01 | Dhal Pradeep K | Amido-amine dendrimer compositions |
| US8273384B2 (en) | 2007-07-02 | 2012-09-25 | Stephen Ray Wurzberger | Process for the preparation of a non-corrosive base solution and methods of using same |
| KR20100045965A (ko) | 2007-07-11 | 2010-05-04 | 도레이 카부시키가이샤 | 가교 폴리알릴아민 또는 그 산부가염 및 그 의약 용도 |
| EP2016947A1 (en) | 2007-07-17 | 2009-01-21 | Chemo Ibérica, S.A. | Novel one step process for preparing cross-linked poly(allylamine) polymers |
| WO2009023544A2 (en) | 2007-08-10 | 2009-02-19 | Ilypsa, Inc. | Dosage unit anion-exchange polymer pharmaceutical compositions |
| US20090156647A1 (en) | 2007-12-12 | 2009-06-18 | Iovate T. & P. Inc. | Method for maintaining physiological pH levels during intensive physical exercise |
| PA8807201A1 (es) | 2007-12-14 | 2009-07-23 | Genzyme Corp | Composiciones farmaceuticas |
| EP2217215A1 (en) | 2007-12-14 | 2010-08-18 | Genzyme Corporation | Coated pharmaceutical compositions |
| WO2009097127A1 (en) | 2008-01-31 | 2009-08-06 | Genzyme Corporation | Pharmaceutical compositions |
| EP2282729A1 (en) | 2008-03-11 | 2011-02-16 | Livionex Inc. | Methods and compositions for treating inflammation and inflammation-related pathologies |
| AU2009235024A1 (en) | 2008-04-08 | 2009-10-15 | Usv Limited | Process for preparation of amine polymer salt |
| WO2009154747A1 (en) | 2008-06-20 | 2009-12-23 | Genzyme Corporation | Pharmaceutical compositions |
| DE102008030046A1 (de) | 2008-06-25 | 2009-12-31 | Ratiopharm Gmbh | Kompaktiertes Polyallylamin-Polymer |
| US20100008988A1 (en) | 2008-07-14 | 2010-01-14 | Glenmark Generics, Ltd. | Tablet compositions of amine polymers |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| US8337824B2 (en) | 2008-08-22 | 2012-12-25 | Relypsa, Inc. | Linear polyol stabilized polyfluoroacrylate compositions |
| WO2010022381A1 (en) | 2008-08-22 | 2010-02-25 | Relypsa, Inc. | Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties |
| KR20110066952A (ko) | 2008-09-25 | 2011-06-17 | 비브 나노, 인코포레이티드 | 중합체 나노입자 및 활성 성분의 제형을 제조하는 방법 |
| US20110268666A1 (en) | 2008-09-29 | 2011-11-03 | Yissum Research Development Company of the Research University of Jerusalem, Ltd. | Novel gastroretentive delivery system |
| WO2010059384A1 (en) | 2008-10-30 | 2010-05-27 | Janssen Pharmaceutica Nv | Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists |
| US20100166861A1 (en) | 2008-12-29 | 2010-07-01 | Kelly Noel Lynch | Pharmaceutical formulations of sevalamer, or salts thereof, and copovidone |
| EP2389168A2 (en) * | 2009-01-22 | 2011-11-30 | USV Limited | Pharmaceutical compositions comprising phosphate-binding polymer |
| WO2011059609A2 (en) | 2009-10-13 | 2011-05-19 | The Regents Of The University Of Michigan | Dendrimer compositions and methods of synthesis |
| EP2490675B1 (en) | 2009-10-22 | 2019-01-23 | Synthon B.V. | Pharmaceutical compositions of sevelamer |
| JP5984675B2 (ja) | 2009-12-07 | 2016-09-06 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | 胃腸障害の療法 |
| CN105017481B (zh) | 2010-02-24 | 2018-10-02 | 瑞立普萨公司 | 用作胆汁酸螯合剂的交联聚乙烯胺、聚烯丙胺和乙烯亚胺 |
| CN102858347B (zh) | 2010-02-24 | 2016-11-02 | 瑞立普萨公司 | 用作胆汁酸螯合剂的聚咪唑 |
| IT1406068B1 (it) * | 2010-07-22 | 2014-02-06 | Medestea Int Spa | Polidesossiribonucleotidi (pdrn) per l'impiego nel trattamento di condizioni di acidosi e composizioni a base di polidesossiribonucleotidi per il suddetto impiego |
| WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| KR101238210B1 (ko) | 2011-06-30 | 2013-03-04 | 엘지전자 주식회사 | 이동 단말기 |
| US20130137772A1 (en) | 2011-11-29 | 2013-05-30 | Raymond J. Bergeron | Hydroxypolyamine salts |
| US20130345303A1 (en) | 2012-06-21 | 2013-12-26 | Keryx Biopharmaceuticals, Inc. | Use of ferric citrate in the treatment of chronic kidney disease patients |
| KR20210005314A (ko) | 2012-10-08 | 2021-01-13 | 리립사, 인크. | 고혈압 및 고칼륨혈증을 치료하기 위한 칼륨-결합제 |
| EP3003327B1 (en) | 2013-06-05 | 2017-08-09 | Tricida Inc. | Proton-binding polymers for oral administration |
| EP3747432A1 (en) | 2013-11-04 | 2020-12-09 | Keryx Biopharmaceuticals, Inc. | Ferric citrate for reducing cardiac failure in chronic kidney disease patients |
| RS61409B1 (sr) | 2014-12-10 | 2021-03-31 | Tricida Inc | Polimeri koji vezuju protone za oralnu primenu opis |
| CN109414453B (zh) | 2016-05-06 | 2023-02-17 | 特里赛达公司 | 用于治疗酸碱失衡的组合物 |
| US10934380B1 (en) | 2017-09-25 | 2021-03-02 | Tricida, Inc. | Crosslinked poly(allylamine) polymer pharmaceutical compositions |
| CA3080651A1 (en) | 2017-11-03 | 2019-05-09 | Tricida, Inc. | Compositions for and method of treating acid-base disorders |
| AU2018360868B2 (en) | 2017-11-03 | 2025-01-02 | Tricida, Inc. | Method of treating acid-base disorders |
| CA3102765A1 (en) | 2018-06-04 | 2019-12-12 | Tricida, Inc. | Method of treating acid-base disorders |
| WO2019236124A1 (en) | 2018-06-04 | 2019-12-12 | Tricida, Inc. | Method of treating acid-base disorders |
| WO2019236639A1 (en) | 2018-06-04 | 2019-12-12 | Tricida, Inc. | Method of treating acid-base disorders |
| US20200306209A1 (en) | 2019-03-27 | 2020-10-01 | Tricida, Inc. | Method of treating acid-base disorders |
-
2017
- 2017-05-05 CN CN201780040511.8A patent/CN109414453B/zh active Active
- 2017-05-05 CA CA3023264A patent/CA3023264A1/en active Pending
- 2017-05-05 WO PCT/US2017/031378 patent/WO2017193050A1/en not_active Ceased
- 2017-05-05 SG SG11201809605PA patent/SG11201809605PA/en unknown
- 2017-05-05 KR KR1020187034960A patent/KR102655774B1/ko active Active
- 2017-05-05 WO PCT/US2017/031395 patent/WO2017193064A1/en not_active Ceased
- 2017-05-05 RU RU2018142943A patent/RU2018142943A/ru unknown
- 2017-05-05 EP EP17737928.6A patent/EP3452057A1/en not_active Withdrawn
- 2017-05-05 US US16/099,024 patent/US11406661B2/en active Active
- 2017-05-05 MY MYPI2018703962A patent/MY197091A/en unknown
- 2017-05-05 US US16/099,045 patent/US20200054669A1/en not_active Abandoned
- 2017-05-05 BR BR112018072714-8A patent/BR112018072714A2/pt not_active Application Discontinuation
- 2017-05-05 EP EP17793497.3A patent/EP3452028A4/en active Pending
- 2017-05-05 AU AU2017261337A patent/AU2017261337A1/en not_active Abandoned
- 2017-05-05 IL IL308673A patent/IL308673A/en unknown
- 2017-05-05 EP EP20204589.4A patent/EP3831395A1/en active Pending
- 2017-05-05 US US16/099,029 patent/US20190209607A1/en not_active Abandoned
- 2017-05-05 IL IL262660A patent/IL262660B2/en unknown
- 2017-05-05 JP JP2018558147A patent/JP7071284B2/ja active Active
- 2017-05-05 WO PCT/US2017/031344 patent/WO2017193024A1/en not_active Ceased
- 2017-05-05 MA MA044875A patent/MA44875A/fr unknown
- 2017-05-05 MA MA054925A patent/MA54925A/fr unknown
- 2017-05-05 MA MA044886A patent/MA44886A/fr unknown
- 2017-05-05 MX MX2018013476A patent/MX2018013476A/es unknown
- 2017-05-05 CN CN202310086355.6A patent/CN116211887A/zh active Pending
-
2021
- 2021-03-04 US US17/192,701 patent/US20210205351A1/en active Pending
- 2021-09-24 US US17/485,177 patent/US11992501B2/en active Active
-
2022
- 2022-05-06 JP JP2022076617A patent/JP2022106914A/ja active Pending
- 2022-08-01 US US17/878,192 patent/US20250009785A1/en active Pending
-
2023
- 2023-04-05 AU AU2023202111A patent/AU2023202111B2/en active Active
-
2025
- 2025-07-17 JP JP2025120716A patent/JP2025157428A/ja active Pending
- 2025-08-15 AU AU2025217383A patent/AU2025217383A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018142943A (ru) | Композиции для лечения нарушений кислотно-основного равновесия | |
| KR101484382B1 (ko) | 수의학적 조성물 | |
| RU2013108857A (ru) | Соединения для лечения/профилактики воспалительных глазных заболевний | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| IL273960B2 (en) | Nonabsorable compositions for use in treating or preventing metabolic acidosis | |
| CA3102765A1 (en) | Method of treating acid-base disorders | |
| EA200800161A1 (ru) | Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций | |
| CA3127926A1 (en) | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa | |
| KR20220042147A (ko) | 브루신 겔 제형 및 그 제조 방법 | |
| RU2014126879A (ru) | Композиции акампросата, способы их применения и содержащие их комбинации | |
| CN103070881A (zh) | 一种阴道抑菌、杀病毒组合物及其应用 | |
| KR101811376B1 (ko) | 경구용 철 결핍증 치료 | |
| Patil et al. | Formulation development and in vitro and in vivo evaluation of gastroretentive floating drug delivery system of Lafutidine | |
| JP2015528509A5 (https=) | ||
| RU2008152691A (ru) | Способ профилактики и лечения мастита у коров | |
| JP2023533617A5 (https=) | ||
| RU2571819C2 (ru) | Иммунометаболический состав с антимикробной активностью | |
| US9446060B2 (en) | Method of producing therapeutic agent | |
| RU2008136081A (ru) | Фармацевтические составы с алифатическими аминными полимерами и способы их производства | |
| Patel | Formulation and evaluation of Omeprazole gastroretentive floating tablets for the treatment of peptic ulcer | |
| US20160287627A1 (en) | Method for suppressing onset of gastric ulcer as adverse effect of drug, oral pharmaceutical composition for suppressing onset of gastric ulcer and method for producing the same | |
| WO2024204698A1 (ja) | 医薬組成物 | |
| RU2017132445A (ru) | Дозы панобиностата для множественной миеломы | |
| CN103222954A (zh) | 一种含洛哌丁胺或其盐酸盐的溶液剂及其制备方法 | |
| CN106551897A (zh) | 一种草乌甲素搽剂及其制备方法与应用 |